Graybug Vision, Inc. GRAY
At closeMar 20, 2023, 4:00 PM EDT
52-week range unavailable
- Market cap
- 120.98M
- Shares out
- 22.00M
- Forward P/E
- -3.31
- Volume
- 24.63K
- Open
- 5.55
- Previous close
- 5.50
- Day's range
- 5.02 – 6.00
- Beta
- 1.20
- Analysts
- Hold
- Price target
- 49.00 (+790.9%)
- Earnings date
- Mar 23, 2023
2Y -44.06 (-94.23%)
Key statistics
- Enterprise value
- 96.70M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -13.66M
- Total cash
- 39.13M
- Total debt
- 203.00K
- Return on equity
- -70.51%
- Short % of float
- 0.17%
- 50-day average
- 7.94
- 200-day average
- 3.30
Analyst view
Consensus: hold
- Target (low)
- 28.00
- Target (mean)
- 49.00
- Target (high)
- 70.00
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 23, 2023
Expected Mar 23, 2023. Consensus EPS estimate -0.45.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 23, 2023 | Dec 1, 2022 | -6.30 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -5.32 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -5.32 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -4.76 | — | — | — |
| Mar 10, 2022 | Dec 1, 2021 | -5.04 | — | — | — |
| Nov 11, 2021 | Sep 1, 2021 | -4.90 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 24, 2023 | Oppenheimer | init | — | Outperform |
| May 19, 2022 | Piper Sandler | main | — | Neutral |
| Mar 17, 2022 | Cantor Fitzgerald | main | — | Overweight |
| May 13, 2021 | SVB Leerink | down | Outperform | Market Perform |
| May 13, 2021 | Needham | down | Buy | Hold |
| Mar 10, 2021 | Wedbush | down | Outperform | Neutral |
About Graybug Vision, Inc.
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- graybug.vision
News
GRAY ANNOUNCES QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE 
GRAY SETS DATE FOR SECOND QUARTER EARNINGS RELEASE AND EARNINGS CONFERENCE CALL 
Graycliff Announces LIFE Financing for Advancing Shakespeare Project 
Grayscale Investments Launches the Lowest Gross Fee Hyperliquid ETP in the U.S. with Grayscale® Hyperliquid Staking ETF (Ticker: HYPG) 
Graycliff Receives Drill Results up to 3030 g/t Gold over 1.0 metre at Shakespeare Gold Project, Ontario 
GRAY ANNOUNCES QUARTERLY CASH DIVIDEND OF $0.08 PER SHARE 
Grayscale Investments® Announces Rebalancing of Multi-Asset Funds for First Quarter 2026 
Graycliff Exploration Announces New CFO and Independent Director 
Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY) 
Graycliff Exploration Closes Oversubscribed Private Placement
Your note
Sign in to keep a note on GRAY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREUIL ROBERT S | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 13, 2023 | 162,119 |
| CAGLE GERALD D | Director | Conversion of Exercise of derivative security | Sep 28, 2020 | 3,322 |
| CLARUS LIFESCIENCES III, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 28, 2020 | 0 |
| FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 28, 2020 | 0 |
| GUERARD FREDERIC | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 2, 2023 | 383,682 |
| KEYOUNG HANSOO MICHAEL | Director | Conversion of Exercise of derivative security | Sep 28, 2020 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 24.01% | 377,267 | 2.07M | Dec 30, 2022 |
| Orbimed Advisors LLC. | 18.93% | 297,384 | 1.64M | Dec 30, 2022 |
| Bml Capital Management, LLC | 5.62% | 88,282 | 485.55K | Dec 30, 2022 |
| Vanguard Group, Inc. (The) | 1.91% | 29,995 | 164.97K | Dec 30, 2022 |
| First Manhattan Company | 1.23% | 19,381 | 106.59K | Dec 30, 2022 |
| Renaissance Technologies, LLC | 0.71% | 11,143 | 61.29K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.48% | 318,437 | 1.75M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.45% | 96,699 | 531.84K | Sep 29, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.30% | 64,000 | 352.00K | Sep 29, 2022 |
| Fidelity Extended Market Index Fund | 0.20% | 43,136 | 237.25K | Nov 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.06% | 13,171 | 72.44K | Nov 29, 2022 |
| Fidelity Total Market Index Fund | 0.03% | 6,561 | 36.09K | Nov 29, 2022 |